Retinol‐binding protein in rheumatoid arthritis

Todesco, S; Punzi, Leonardo; Meani, Alessandro; Gambari, P F; Borsatti, A.

doi:10.1002/art.1780240121

Cited by 20 publications

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In Italy, disease prevalence is 4.1% in the general population (6.9% in women and 0.3% in men) [ 1 ]. FM shows a bimodal pattern of incidence: a first peak between 25 and 35 years and a second between 45 and 55 years [ 2 ]. This syndrome is characterized by widespread chronic pain, tenderness in muscles and deep tissues, and fatigue accompanied by other non-specific symptoms, including sleep disturbances.…”

Section: Introductionmentioning

confidence: 99%

Palmitoylethanolamide in Fibromyalgia: Results from Prospective and Retrospective Observational Studies

et al. 2015

View full text Add to dashboard Cite

IntroductionFibromyalgia syndrome (FM) is characterized by persistent pain which is often refractory to common analgesic therapies and is particularly disabling. The objective of this study was to evaluate the therapeutic efficacy of duloxetine (DLX) + pregabalin (PGB) in patients suffering from FM and the possible added benefit of the lipid signaling molecule, palmitoylethanolamide (PEA). PEA is well-documented to exert anti-inflammatory, analgesic, and pain-relieving effects at both the preclinical and clinical level.MethodsA total of 80 patients were recruited in two steps. The first was a retrospective observational study comprising 45 patients. This patient group received DLX + PGB for 6 months. The second step was a prospective observational study with 35 patients. Patients in this cohort began treatment with DLX + PGB at the same dosage as for the retrospective study plus micronized PEA (PEA-m®; Epitech Group, Italy) and ultramicronized PEA (PEA-um®; Epitech Group, Italy) for 3 months. Positive tender points (TPs), pain evoked, and pain intensity were evaluated at baseline and after 3 and 6 months in both studies. Statistical analyses were employed for comparison of data within the two studies and between them.ResultsThe retrospective observational study (DLX + PGB), after 3 months of treatment showed a decrease of positive TPs, pain evoked, and pain intensity. After 6 months of treatment, these parameters had further improvement. In the prospective observational study (DLX + PGB + PEA), PEA introduction after 3 months of therapeutic regimen with DLX + PGB provided a significant improvement in pain symptoms, with a further reduction in the number of TPs and significant reduction in pain, compared to combined DLX + PGB only (p < 0.0001 for TPs and Visual Analog Scale comparisons). None of the patients experienced adverse side effects.ConclusionOur study confirms the efficacy of DLX + PGB and demonstrates as well the added benefit and safety of PEA in the treatment of pain in patients affected by FM.Electronic supplementary materialThe online version of this article (doi:10.1007/s40122-015-0038-6) contains supplementary material, which is available to authorized users.

show abstract

Section: Introductionmentioning

confidence: 99%

Palmitoylethanolamide in Fibromyalgia: Results from Prospective and Retrospective Observational Studies

et al. 2015

View full text Add to dashboard Cite

show abstract

“…6 Despite these findings there has been no comprehensive study concerning the nutritional status in patients with RA. Our aim, therefore, was to assess whether malnutrition is an associated feature of RA and, if present, to determine its cause.…”

mentioning

confidence: 99%

Nutritional status in patients with rheumatoid arthritis.

Helliwell¹,

Coombes²,

Moody³

et al. 1984

Annals of the Rheumatic Diseases

View full text Add to dashboard Cite

“…Come malattia autoimmune può manifestarsi a livello sistemico con l'interessamento di diversi organi e apparati (1). Il sospetto di SS si ha in seguito al riscontro di xerostomia, xeroftalmia, artralgie, mialgie; tali sintomi Reumatismo, 2008;60(2):141-149 Le cause della SS non sono ancora completamente note, ma si ritiene, come per altre malattie autoimmuni, che vi contribuiscano fattori genetici: associazione con il DR3 e il DRw52, ormonali, immunologici e virali come infezione da CMV, virus di Epstein Barr, HTLV-1, HIV (5,6). La diagnosi di SS, secondo l'American-European Consensus Group, si avvale oltre che di criteri clinici, anche di indici bioumorali ed indagini strumentali (3).…”

unclassified

“…È un'indagine non invasiva, innocua, ripetibile, di basso costo ed elevata accuratezza diagnostica (10). Le ghiandole salivari sono strutture superficiali, per cui lo studio ecografico va effettuato con sonde di tipo "small parts", ossia sonde dotate di trasduttori ad alta frequenza (7,5 MHz o 10 MHz). L'esame viene eseguito con paziente in decubito supino con il collo leggermente iperesteso, per lo studio delle sottomandibolari, per le parotidi anche con capo ruotato controlateralmente al lato in esame.…”

unclassified